Table 3.

Prognostic effect of the acute or stress hyperglycemia on AKI risk

AKI	Acute hyperglycemia (ABG ≥ 198 mg/dL)		Stress hyperglycemia (SHR ≥ 1.23)
	OR (95% CI)	P value	OR (95% CI)	P value
Overall DM	1.60 (1.03–2.49)	0.036	2.43 (1.49–3.95)	< 0.001
History of DM
Newly diagnosed	1.36 (0.54–3.42)	0.511	2.17 (1.04–5.13)	0.039
Known before	1.61 (0.94–2.75)	0.079	2.73 (1.53–4.84)	0.001
Duration of DM
< 10 years	1.30 (0.70–2.39)	0.398	2.05 (1.05–4.01)	0.035
≥ 10 years	2.02 (0.98–4.15)	0.056	3.10 (1.45–6.63)	0.003
Prior treatment
No medication	1.37 (0.65–2.91)	0.402	2.76 (1.13–4.95)	0.032
Oral antidiabetics	1.80 (0.77–4.21)	0.173	2.61 (1.06–6.42)	0.036
Insulin use	1.19 (0.51–2.75)	0.678	2.56 (1.06–6.19)	0.037

Multivariate logistic regression analysis for prognostic effect of acute or stress hyperglycemia on AKI risk in overall and subgroups of DM patients. Acute hyperglycemia was defined as ABG ≥ 198 mg/dL (11 mmol/L). Stress hyperglycemia was defined as SHR ≥ 1.23. This cut-off value of SHR was identified with maximum Youden index in all patients for AKI prediction using ROC analysis. Patients were stratified according to diabetic history, duration and prior treatment

OR was adjusted for age, gender, MI classification (STEMI or NSTEMI), PCI treatment (with or without) and peak TnI in the multivariate model

ABG, admission blood glucose; SHR, stress hyperglycemia ratio; DM, diabetes; AKI, acute kidney injury; OR, odds ratio; CI, confidence interval